Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours

Anna Sowa-Staszczak, Dorota Pach, Jolanta Kunikowska, Leszek Krolicki, Agnieszka Stefanska, Monika Tomaszuk, Monika Buziak-Bereza, Renata Mikolajczak, Marta Matyja, Aleksandra Gilis-Januszewska, Agata Jabrocka-Hybel, Malgorzata Trofimiuk (+1 others)
2011 Endokrynologia Polska  
The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, (90)Y labelled Tyr3-octreotate, ((90)Y-DOTATATE) in neuroendocrine tumours (NETs). 46 patients with disseminated or non-operable NET were enrolled in this study. The (90)Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m(2) administered in three to five cycles,
more » ... ee to five cycles, repeated every four to nine weeks. Before and after the therapy, blood tests for haematology, kidney and liver function, and chromogranin A were performed. Out of 46 (90)Y-DOTATATE treated patients, one died before completing the therapy and 16 died after completing the therapy, among them one due to myocardial infarction. After 12 month follow-up, stabilisation of disease was observed in 47%, partial remission in 31%, and progression in 9% of the 45 patients who completed the therapy. Five patients died before completion of 12 months of follow-up. One of the patients died due to myocardial infarction. In one case, the information after 12 months is incomplete. The progression free survival was 37.4 months. During 12 months follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. A transient increase of creatinine level (within normal ranges) and decrease of GFR values were found. NETs (90)Y-DOTATATE therapy results in symptomatic relief and tumour mass reduction. The mild critical organ toxicity does not limit the PRRT of NETs.
pmid:22069099 fatcat:drfeydtovzbhvkm7t3ukvbipyu